



## Pediatric Atopic Dermatitis: Clinical Scenarios

### Clinical Brief #3 – Pathogenesis and Wrap Up

### References

#### Tweet 2 References:

Barbarot S, Silverberg JI, Gadkari A, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. *J Pediatr*. 2022;246:220-226.

Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. *Allergol Int*. 2018;67:3-11.

Eichenfield LF, Stripling S, Fung S, Cha A, O'Brien A, Schachner LA. Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. *Pediatric Drugs*. 2022;24:293-305.

Erdogan Y, Erturan I, Aktepe E, Akyıldız A. Comparison of quality of life, depression, anxiety, suicide, social anxiety and obsessive-compulsive symptoms between adolescents with acne receiving isotretinoin and antibiotics: a prospective, non-randomised, open-label study. *Pediatr Drugs*. 2019;21:195-202.

Forer E, Tripto IG, Bari R, Shaki D, Goldbart A, Horev A. Effect of paediatric atopic dermatitis on parental sleep quality. *Acta Derm Venereol*. 2023;103:adv00879.

Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. *Children (Basel)*. 2021;8:1057.

Lee DG, Gui XY, Mukovozov I, Fleming P, Lynde C. Sleep disturbances in children with atopic dermatitis: a scoping review. *J Cutan Med Surg*. 2023;27:157-164.

Manjunath J, Silverberg JI. Atopic dermatitis is associated with multiple behavioral problems in US children and adolescents. *Dermatitis*. 2022;33:S52-S60.

Manjunath J, Silverberg NB, Silverberg JI. Association of atopic dermatitis with poor school behaviours in US children and adolescents. *J Eur Acad Dermatol Venereol*. 2022;36:e346-e348.

Su W, Chen H, Gao Y, et al. Anxiety, depression and associated factors among caretakers of children with atopic dermatitis. *Ann Gen Psychiatry*. 2022;21:12.

Wan J, Mitra N, Hooper SR, Hoffstad OJ, Margolis DJ. Association of atopic dermatitis severity with learning disability in children. *JAMA Dermatol*. 2021;157:1-7.

Zhou NY, Nili A, Blackwell CK, et al. Parent report of sleep health and attention regulation in a cross-sectional study of infants and preschool-aged children with atopic dermatitis. *Pediatr Dermatol*. 2022;39:61-68.



### **Additional References:**

Chong AC, Visitsunthorn K, Ong PY. Genetic/environmental contributions and immune dysregulation in children with atopic dermatitis. *J Asthma Allergy*. 2022;15:1681-1700.

Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet*. 2021;397:2151-2168.

Manjunath J, Silverberg NB, Silverberg JI. Association of atopic dermatitis with delinquent behaviors in US children and adolescents. *Arch Dermatol Res*. 2022;314:975-982.

Moniaga CS, Tominaga M, Takamori K. The pathology of type 2 inflammation-associated itch in atopic dermatitis. *Diagnostics (Basel)*. 2021;11:2090.

Paller AS, Beck LA, Blauvelt A, et al. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—a pooled analysis of trial data. *Pediatr Dermatol*. 2022;39:187-196.

Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2022;400:908-919.

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*. 2018;4:1.

### **Glossary**

- AD, atopic dermatitis
- Baso, basophils
- CCL2, chemokine ligand 2
- CXCL, chemokine ligand
- DRG, dorsal root ganglion
- EOS, eosinophils
- IgE, immunoglobulin E
- IL, interleukin
- ILC2, innate lymphoid cells type 2
- JAK, Janus kinase
- KC, Kenyon cell
- OSMR, oncostatin-M-specific receptor
- PAR2, protease activated receptor 2
- R $\alpha$ , receptor alpha
- ST, suppressor of tumorigenicity
- STAT, signal transducer and activator of transcription
- TH2, T helper 2 cell
- TYK, tyrosine kinase
- TRPV, transient receptor potential vanilloid
- TRPA, transient receptor potential ankyrin
- TSLP, thymic stromal lymphopoietin



TSLPR, TSLP receptor.

TYK, tyrosine kinase

w/, with